New data suggests that retatrutide, a dual-action medication, could represent a major improvement in weight management. This therapy combines the effects of a GLP-1 agonist and a GIP agonist , seemingly offering a more outcome than available therapies . Study research have revealed promising results , including considerable reductions in body and